medi-cal no longer covering glp-1 California's Proposal to Cut Coverage for California has ended adult Medi-Cal
Description
At present, tirzepatide is the leading GLP-1/GIP dual agonist and has been approved for marketing in many countries, including the US, Europe and Japan, for the treatment of T2D
The same orally administered drug was approved in the US last month
They do accept HSA and FSA funds
Hvistendahl M, Brandt CF, Tribler S, et al
There is limited evidence that supplements like berberine, fiber, and probiotics may help raise GLP-1 in the body
